Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 08, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares rather than a comprehensive financial performance report.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Share Purchase Price (ISA): £12.41 per Ordinary Share.
- Share Purchase Price (ShareReward Plan): £12.40 per Ordinary Share.
Material Changes
The filing details changes in the shareholding of Director Mr. J S Heslop on April 07, 2005:
- Acquisition of Ordinary Shares via a Single Company ISA.
- Acquisition of 7 Ordinary Shares under the Dividend Reinvestment element of the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Points
- Verify the total number of shares acquired by Mr. J S Heslop under the Single Company ISA, as the specific quantity is not stated in the text.
- Confirm the total aggregate shareholding of Mr. J S Heslop following these transactions.
- Review the full terms of the ShareReward Plan entered into on October 5, 2001, to understand the context of the dividend reinvestment.